Resectable Non–Small Cell Lung Cancer: Neoadjuvant Tr

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Related Keywords

, Recent Updates , Translating Evidence , Clinical Practice , Small Cell Lung Cancer , Neoadjuvant Treatment Strategies , Lung Cancer , Non Small Cell Lung Cancer , Nsclc , Trio Therapy , Immunotherapy , Immune Checkpoint Inhibitors , Neoadjuvant Therapy , Perioperative Therapy , Neoadjuvant Chemotherapy , Checkmate 816 , Nivolumab Therapy , Neoadjuvant Nivolumab , Molecular Testing , Genetic Testing , Mutational Analysis , Pdl1 Status , Pdl1 Expression , Nadim Ii , Nadim 2 , Pathologic Complete Response , Path Cr , Aegean Study , Aegean Trial , Durvalumab , Neoadjuvant Durvalumab ,